Vancomycin heteroresistance (hVISA) in MRSA links to treatment failure and supports a revised PAP-AUC threshold Authors: Nikos Fatsis-Kavalopoulos, Yong Kyun Kim, Yong Pil Chong, Seongman Bae, So Yun Lim, Yang Soo Kim, Dan I Andersson Published: 2025 ABSTRACT AbstractHeteroresistance to vancomycin among methicillin-resistant Staphylococcus aureus (MRSA) remains a diagnostic and therapeutic problem in clinical microbiology. In this prospective cohort study of 842 adult patients with MRSA bacteremia in S. Korea, we investigate the prevalence, risk factors, and clinical implications of the heteroresistant vancomycin-intermediate S. aureus (hVISA) phenotype. The hVISA phenotype is detected in 22% of cases. Multivariable regression analysis reveals strong positive associations between hVISA and hospital-acquired infection, prior anti-MRSA therapy, vancomycin exposure, and particularly vancomycin MIC (odds ratio 15.2 per 1 mg/L increase, p < 0.001). Strikingly, patients infected with hVISA strains have a lower 90-day mortality compared to those with fully susceptible strains (hazard ratio 0.66, p = 0.019), suggesting a possible trade-off between resistance and virulence. However, in hVISA strains treated with vancomycin, outcomes reverse: mortality more than doubled (HR 2.5, p < 0.001), bacteremia persisted longer, and relapse rates increased fivefold. Using maximally selected rank statistics, we identify a PAP–AUC threshold of 0.65 as the first clinically derived breakpoint predictive of mortality risk, providing an actionable definition of vancomycin heteroresistance. These findings underscore the clinical relevance of hVISA, and support routine testing for heteroresistance to inform treatment decisions.Subject terms: Bacteriology, Medical research, Antimicrobial resistance Introduction Methicillin-resistant S. aureus (MRSA) remains one of the most formidable challenges in clinical microbiology and infectious disease management. Identified as a priority pathogen by the World Health Organization (WHO)1, MRSA is a leading cause of healthcare-associated infections worldwide2,3, associated with severe morbidity3–5, prolonged hospital stays5,6, and increased mortality3–5,7. The continued emergence of MRSA strains with reduced susceptibility to frontline antibiotics poses a significant threat to public health, prompting the need for continuous surveillance and the development of effective therapeutic strategies8. Among the diverse resistance mechanisms in MRSA, one that has garnered increasing attention is heteroresistance, a phenotype where a bacterial population contains a small subpopulation of cells with significantly higher resistance levels compared to the susceptible majority9,10. In the context of MRSA, this phenomenon has been most notably observed as heteroresistant vancomycin (VAN)-intermediate S. aureus (hVISA)11,12. The hVISA phenotype is particularly concerning because it erodes the efficacy of VAN, which remains the cornerstone of treatment for severe MRSA infections, especially bloodstream infections13 and infective endocarditis14,15. As VAN is often the last line of defence against MRSA, the emergence of hVISA threatens to diminish one of the most valuable therapeutic options available. The hVISA phenotype was first described in Japan in 199712, when isolates from patients with persistent MRSA bacteremia demonstrated intermediate resistance to VAN despite being classified as susceptible by standard MIC testing. Since then, the clinical implications of hVISA have remained a topic of debate16. The phenotype is defined microbiologically by the population analysis profile–area under the curve (PAP–AUC) method, where the test isolate’s AUC relative to the reference strain (Mu3, ATCC 700698) is ≥0.911. This method is considered the gold standard, but it is labour-intensive and time-consuming, limiting its routine use. In addition, and importantly, the AUC cutoff value for hVISA has no established link to treatment outcome, limiting its usefulness in clinical settings. Several studies have identified key risk factors associated with the development of the hVISA phenotype, primarily linked to antibiotic exposure and patient comorbidities. The most consistently reported factor is prior VAN use, which significantly increases the likelihood of hVISA emergence17,18. Other studies have also highlighted chronic renal failure, prolonged hospitalization, and immunosuppression as important predictors, likely due to increased antibiotic pressure and reduced host defenses19,20. Additionally, hospital-acquired infections and higher VAN MICs have been linked to hVISA, reflecting the role of healthcare settings and intense antibiotic use in fostering heteroresistance21,22. Despite over two decades of research, there remains no consensus on the clinical relevance of hVISA. Some studies have linked the phenotype to increased morbidity, prolonged bacteremia, and treatment failure17,19,23–27, while others have found no significant impact on patient outcomes, including mortality18,22,23,28,29. The inconsistency between clinical trials and observational studies has made it difficult to draw definitive conclusions about whether hVISA should be regarded as a marker of poor prognosis. One possible reason for the variability in reported outcomes is the way hVISA is studied. Some investigations have focused solely on the phenotype itself, assessing its presence and correlating it with clinical outcomes, while others have examined the interaction between hVISA and VAN therapy, analyzing whether the combination of heteroresistance and VAN treatment influences outcomes differently. This duality in study designs has contributed to divergent findings and conflicting interpretations, making it challenging for clinicians to determine the true clinical impact of hVISA. In this study, we aimed to address these gaps by conducting a large prospective cohort analysis to assess both the prevalence and clinical implications of the hVISA phenotype in MRSA bacteremia. Uniquely, we adopted a dual approach to examine not only the independent effects of the phenotype but also its interaction with VAN therapy. Furthermore, we identified potential risk factors associated with hVISA emergence and determined an AUC breakpoint for increased risk of mortality, providing clinicians with evidence to guide early identification and more tailored therapeutic strategies. Results Prevalence and risk factors of hVISA During the study period, we initially identified 1592 patients with a first episode of MRSA bacteremia. After applying predefined exclusion criteria, including polymicrobial bacteremia (n = 207) and discharge prior to confirmation of a positive blood culture (n = 57), a total of 1328 patients remained for the final cohort. Among these, 842 patients with MRSA bloodstream isolates who underwent PAP testing to determine hVISA status met the inclusion criteria. Of these, 184 isolates were identified as hVISA, yielding a prevalence of 22% in the study cohort (characteristics of which are shown in Table 1). Table 1Characteristics of hVISA and non hVISA subcohorts, age, CCI (=Charlson Comorbidity Index) score, McCabe score, duration of SAB, Pitt score, sepsis grade are noted as median and rangehVISA patients (184)non hVISA patients (658)Age63.0 (20.0 92.0)65.0 (19.0–98.0)Female24% (44)39% (256)Male76% (140)61% (402)CCI score3.0 (0.0–9.0)3.0 (0.0–13.0)McCabe score3.0 (1.0–3.0)3.0 (1.0–3.0)Survival within 90 days from positive index culture68% (125)70% (460)Duration of SAB1.0 (1.0–68.0)1.0 (1.0–74.0)Recurrence of SAB within 90 days from positive index culture6% (12)5% (32)Pitt score1 (0.0–18.0)1.0 (0.0–13.0)Sepsis grade2.0 (1.0–4.0)2 (1.0–4.0)Admission in the ICU31% (57)19% (125)VAN treatment80% (147)82% (539)Previous VAN treatment34% (62)16% (105)Previous any AB treatment82% (150)57% (375)Gender, mortality within 90 days from positive index culture, recurrence of SAB within 90 days from positive index culture, admission to the ICU, and antibiotic treatments are noted as percentage of patients and number. Characteristics of hVISA and non hVISA subcohorts, age, CCI (=Charlson Comorbidity Index) score, McCabe score, duration of SAB, Pitt score, sepsis grade are noted as median and range Gender, mortality within 90 days from positive index culture, recurrence of SAB within 90 days from positive index culture, admission to the ICU, and antibiotic treatments are noted as percentage of patients and number. Multivariable logistic regression was used to assess associations between clinical variables and the hVISA phenotype, aiming to identify potential patient-level risk factors (Fig. 1). An interaction term between age and sex was included to evaluate whether the association between age and hVISA differed by sex, and all associated Odds ratios and p values are shown in Table 2. Odds ratios of Risk factors associated with hVISA. Shown as value with 95% CI (error bars denote CI), * denotes 0.001